Oculis Announces Pricing of $40.25 Million Public Offering
ZUG, Switzerland and BOSTON, May 31, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to...
Stay updated with breaking news from Oculis Sa. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ZUG, Switzerland and BOSTON, May 31, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to...
Press Release: Oculis Strengthens its Scientific Advisory Board with World-Leading Ophthalmology Experts to Support Pipeline Development Oculis Strengthens its Scientific Advisory Board with World-Leading
Oculis appoints Dr. Bastian Dehmel as Chief Development Officer Former Amgen Global Development Leader/OxThera CMO joins Oculis as Chief Development...
Oculis appoints Dr. Bastian Dehmel as Chief Development Officer - read this article along with other careers information, tips and advice on BioSpace